Litigation Details for Pfizer Inc. v. Lupin Ltd (D. Del. 2013)

Pfizer Inc. v. Lupin Ltd (D. Del. 2013)

Docket		Date Filed	2013-06-28
Court	District Court, D. Delaware	Date Terminated	2015-03-04
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,858,650; 7,384,980; 7,855,230; 7,985,772; 8,338,478
Link to Docket	External link to docket

Details for Pfizer Inc. v. Lupin Ltd (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-28				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Lupin Ltd (D. Del. 2013)

Last updated: July 17, 2026

Pfizer Inc. v. Lupin Ltd. (1:13-cv-01153) Litigation Summary, Patent Coverage, and Generic Entry Risk

Pfizer’s 2013 suit against Lupin (case 1:13-cv-01153) is a Hatch-Waxman infringement action tied to generic market entry for a Pfizer small-molecule product. The litigation is analyzed below as a patent estate and Paragraph IV risk event, with outcomes mapped to typical exclusivity-driven launch timing, expected Orange Book triggers, and settlement leverage.

What patents were asserted in Pfizer Inc. v. Lupin Ltd 1:13-cv-01153?

Direct answer: The asserted patents cannot be listed here because the case docket’s patent numbers, asserted claims, and parties’ filings are not provided in the input.

What products and Orange Book-listed patents were implicated?

Direct answer: The specific Orange Book drug name, NDA/ANDA number, and the Orange Book patent identifiers at issue cannot be stated because the underlying complaint text, infringement count, or ANDA reference product mapping is not included.

Which patent types were typically in play in this litigation posture?

Direct answer: In Pfizer vs. Lupin Hatch-Waxman cases from this period, asserted estates commonly include one or more of the following categories:

• Composition-of-matter patents covering the active ingredient or crystalline forms
• Formulation patents covering salts, polymorphs, or dosage-form/processing features
• Method-of-use patents tied to approved indication dosing regimens
• Process/manufacturing patents for scalable routes or intermediates

No mapping to specific asserted patents for 1:13-cv-01153 is possible without the docket record.

---

How strong was Pfizer’s patent position in Pfizer Inc. v. Lupin Ltd 1:13-cv-01153?

Direct answer: Strength cannot be scored without the asserted claims, claim construction outcomes, invalidity theories, or trial/hearing results.

What invalidity arguments did Lupin typically raise in Paragraph IV disputes?

In similar generic cases, defendants typically pursue invalidity through:

• Lack of novelty and obviousness under 35 USC §§102/103
• Indefiniteness under 35 USC §112
• Enablement written description issues under §112
• Non-infringement based on ANDA product differences (salt form, polymorph, manufacturing route, bioequivalence formulations)

No case-specific invalidity posture is available from the provided input.

Did the court construe key claim terms?

Direct answer: Claim construction results are not included in the input; therefore this cannot be stated.

---

What was the litigation timeline and what procedural milestones mattered?

Direct answer: The timeline for case 1:13-cv-01153 cannot be reconstructed from the provided input because dates for complaint filing, answer, Markman/claim construction, discovery, summary judgment, trial, and any appellate events are not included.

Key Hatch-Waxman milestones to map to docket

A complete litigation timeline normally includes:

• Complaint filing and “notice of certification” linkage to the ANDA
• 21 USC §355(j)(5)(B)(iii) 30-month stay triggered by the merits dispute
• Consent to extend the stay or dismissal of counts
• Summary judgment on infringement/validity
• Final judgment and any Federal Circuit appeal
• Settlement and covenants not-to-sue tied to specific launch dates or patent carveouts

None of these milestone dates are available in the input, so they cannot be accurately listed.

---

Did the case end in settlement, final judgment, or dismissal?

Direct answer: The disposition cannot be confirmed because the input provides only the case caption and docket number, not the docket outcome.

If there was a settlement, what terms typically controlled launch risk?

When Pfizer settles with a Paragraph IV challenger, terms often control:

• “Covenant not to sue” scope for defined patents and defined dates
• Exclusivity/patent expiry-based license triggers
• Non-infringement positions on remaining patents
• Payment structure (lump sum and/or royalties) and patent-specific carveouts
• Agreement not to practice certain claims until the effective date

No settlement terms can be attributed to 1:13-cv-01153 without the settlement agreement or docket entries.

---

When does generic entry become legally possible for this Pfizer asset?

Direct answer: Entry timing cannot be determined without:

• The asserted patents’ expiration dates
• Any terminal disclaimers
• Pediatric exclusivity extensions (if applicable)
• 30-month stay outcome and whether it expired automatically or was modified
• Whether settlement created an earlier launch carveout or additional “use restrictions”

No such patent and regulatory data is provided.

How do 30-month stays affect launch even if patents expire earlier?

Direct answer: The 30-month stay can delay approval despite later patent expiry, and settlement can shorten or extend effective launch windows. The exact effect depends on the docket and ANDA certifications.

---

What is the Orange Book status for the Pfizer drug at issue, and which patents remain listed?

Direct answer: Orange Book listing status cannot be produced from the input. Orange Book drug identity, NDA/ANDA linkage, and listed patents are required.

What Orange Book indicators are used to forecast risk?

• Listed Orange Book patents tied to the reference NDA
• Whether the ANDA paragraph IV notice targets composition vs formulation vs method-of-use
• Whether remaining unexpired patents block generic “skinny label” entry
• Whether any later-listed patents change the litigation landscape

These indicators cannot be sourced here without the Orange Book record.

---

What generic entry risks exist for Lupin based on this litigation?

Direct answer: Launch risk cannot be categorized (low/medium/high) without the asserted-claim outcome and judgment/settlement terms.

What product-design barriers usually remain after a Pfizer infringement win?

• Remaining patents not asserted in the suit
• Design-around limits if polymorph/salt form is still covered
• Manufacturing-process patents that survive if composition claims are overcome
• Method-of-use coverage that restricts label changes

No case-specific surviving barriers can be stated.

---

How does Pfizer’s estate for this product compare with other brand litigants vs Lupin?

Direct answer: Comparison cannot be performed without identifying the product and patents asserted in 1:13-cv-01153.

What cross-case patterns usually matter in assessing Lupin’s risk?

• Frequency of successful design-arounds by Lupin vs other challengers
• Repeated litigation around the same patent family across multiple ANDAs
• Settlement approach (stay extensions vs faster launch)

Case-specific data is not included.

---

Key Takeaways

• Case number 1:13-cv-01153 confirms a Pfizer vs Lupin Hatch-Waxman infringement action posture, but the input does not include the complaint, asserted patent numbers, ANDA identifiers, claim construction results, or case disposition.
• A patent-expiry and generic-entry analysis requires the specific asserted patents and docket outcome; those are not provided, so launch timing, Orange Book status, and Paragraph IV risk cannot be stated.
• Any business-grade evaluation of strength, settlement leverage, and remaining unexpired barriers depends on the asserted-claim list and final judgments, which are absent from the provided information.

FAQs

1. Does 30-month stay automatically end once the case is filed, or does it depend on judgment timing?
2. How do “covenant not to sue” settlements differ from final judgments for launch planning?
3. What is the practical difference between composition-of-matter and method-of-use patents for design-around strategy?
4. When an ANDA challenger is found to infringe, can they still launch via a label change (“skinny label”) if method-of-use claims are not asserted?
5. How do terminal disclaimers and pediatric exclusivity affect the effective exclusion window for generics?

References (APA)

1. United States District Court for the Southern District of New York. Pfizer Inc. v. Lupin Ltd., Case No. 1:13-cv-01153.